Compare AQST & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | ZVRA |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 562.2M |
| IPO Year | 2007 | 2015 |
| Metric | AQST | ZVRA |
|---|---|---|
| Price | $4.77 | $12.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $9.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 3.4M | 805.7K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | $67,430,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $10.08 | $37.27 |
| Revenue Next Year | $49.60 | $53.42 |
| P/E Ratio | ★ N/A | $16.27 |
| Revenue Growth | 0.77 | ★ 350.91 |
| 52 Week Low | $2.94 | $7.16 |
| 52 Week High | $7.55 | $15.04 |
| Indicator | AQST | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 53.00 |
| Support Level | $4.03 | $11.39 |
| Resistance Level | $5.10 | $12.19 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 48.53 | 46.95 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.